Oxybutynin and Omega-3 for OAB (Overactive Bladder)
Status:
Terminated
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
We aim to evaluate whether the addition of Omega-3 fatty acids to oxybutynin, a standard
first-line treatment for overactive bladder syndrome, will improve symptoms and quality of
life. Secondarily, we will evaluate whether Omega-3 fatty acids help reduce the adverse
effects of oxybutynin.
Hypothesis
- Primary: Omega-3 will enhance the beneficial role of oxybutynin in the treatment of
overactive bladder (OAB)
- Secondary: Omega-3 will reduce the side effects of dry eyes and constipation associated
with oxybutynin